Video

Dr. Ko on Unmet Needs in PD-L1–Negative TNBC

Author(s):

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

Heidi Ko, DO, assistant professor of Medicine, medical oncologist, Mays Cancer Center at UT Health San Antonio, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer (TNBC).

Chemotherapy remains the standard-of-care frontline therapy for patients with PD-L1–negative TNBC, and there have not been many data collected from clinical trials regarding this patient population, Ko says. Future studies examining the use of immunotherapy in combination with antibody-drug conjugates or other targeted agents as a first-line therapy could produce other potential treatment options for these patients, Ko explains.

Notably, ongoing studies are examining the frontline use of a PARP inhibitor plus immunotherapy in patients with TNBC harboring BRCA mutations, and these studies include patients with PD-L1–positive and –negative disease, Ko concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center